Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases

Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases

Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.

Abstract: A cyclic tetrapeptide compound of the formula (I): wherein R1 is hydrogen; R2 is lower alkyl, aryl, optionally substituted ar(lower)alkyl, heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl; R3 and R4 are each independently hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic(lower)alkyl or cyclo(lower)alkyl(lower)alkyl, or R3 and R4 are linked together to form lower alkylene or condensed ring, or one of R3 and R4 is linked to the adjacent nitrogen atom to form a ring; R5 is lower alkylene or lower alkenylene, Y is [wherein RY1 is hydrogen, halogen or optionally protected hydroxy, RY2 is hydrogen, halogen, lower alkyl or phenyl, and RY3 is hydrogen or lower alkyl]; R8 is hydrogen or lower alkyl; and n is an integer of 1 or 2, or a salt thereof.

Abstract: The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-? mediated diseases.

Abstract: A compound (Ia): wherein the variables are defined in the specification, its prodrug or a pharmaceutically acceptable salt thereof useful in the treatment of angina, hypertension etc.

Abstract: Novel anthranilic acid derivatives having an inhibiting activity of cGMP-PDE are represented by the formula I where A is a lower alkylene group: 1

Abstract: Compounds of formula (I) where R1 is hydrogen; R2 is nitro, cyano or halo(lower)alkyl; R3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R4 is a group CR6R7R8 wherein R6 and R7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R8 is hydrogen; its prodrug and a salt thereof.

Abstract: Compounds of the formula (I): ##STR1## and their pharmaceutically acceptable compositions are useful in inhibiting the activity of cyclic guanosine 3',5'-monophosphate phosphodiesterase.

Abstract: A new process for preparing a compound of the formula: ##STR1##

Abstract: A compound of the formula (I): ##STR1## wherein R.sup.1 is an optionally protected carboxy(lower)alkyl, R.sup.2 is a hydrogen, an optionally substituted aryl or a carboxy,X is a bond, --0--, --NH-- or a cycloalkylene, andY is an alkylene which may be interrupted by an oxygen atom, an alkenylene or an alkadienylene,or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a testosterone 5.alpha.-reductase inhibitor and effective against testosterone 5.alpha.-reductase-mediated diseases such as prostatism, prostatic hypertrophy, prostatic cancer, alopecia, hirsutism (e.g. female hirsutism), androgenic alopecia (or male-pattern baldness), acne (e.g. acne vulgaris, pimple), and other hyperandrogenisms.

Abstract: A technique, specifically apparatus and an accompanying method, for use in, e.g., a "host" operating system (610), for properly updating a dynamically alterable channel program that controls an input/output (I/O) device so as to emulate a "guest" computer system, that employs dynamic address translation (DAT) in an I/O channel sub-system (150), on a "host" computer system (10) that does not. This technique performs this updating in a manner that significantly increases channel throughput so as to substantially reduce a performance degradation that would otherwise result from a lack of channel DAT on the host system. Specifically, our technique relies on program controlled interrupt (PCI) chaining coupled with use of "just-in-time" translation of each new virtual channel program segment generated by a guest operating system (620) and corresponding updating of channel program (415) then executing on the host computer system.

Abstract: This invention relates to heterocyclic derivatives useful for treating or preventing testosteron 5.alpha.-reductase mediated diseases such as alopecia, ache, prostatism and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to uses thereof.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is carboxy or pharmaceutically acceptable salts and esters thereof;R.sup.2 is hydrogen, lower alkyl or halogen;R.sup.3 is phenyl, naphthyl, phenyl or naphthyl each substituted by from one to three C.sub.1-6 alkyl groups, mono-, di- or triphenyl (C.sub.1-6)alkyl; or substituted mono-, di- or triphenyl (C.sub.1-6) alkyl;A is lower alkylene which may be substituted by oxo or lower alkenylene,Q is carbonyl or lower alkylene,X is ##STR2## in which R.sup.4 is hydrogen or C.sub.1-6 alkyl, andR.sup.5 is hydrogen, C.sub.1-6 alkyl or Y--Z--R.sup.3,Y is a bond or lower alkylene,Z is lower alkylene ##STR3## in which R.sup.6 is hydrogen, (C.sub.1 -C.sub.6) alkyl, mono-, di- or triphenyl(C.sub.1-10) alkyl, C.sub.1-6 alkyl or lower alkoxycarbonyl substituted mono-, di- or triphenyl(C.sub.1-6)alkyl or pharmaceutically acceptable carboxylic acid acyl, and pharmaceutically acceptable salts thereof. The compound is useful as a testosterone 5.alpha.-reductase inhibitor.

Abstract: Indole derivatives of the following formula: ##STR1## wherein R.sup.1 is carboxy(lower)alkyl or protected carboxy(lower)alkyl,R.sup.2 is hydrogen, lower alkyl or halogen,R.sup.3 and R.sup.4 are each hydrogen or lower alkyl,R.sup.5 is ar(lower)alkyl which may have suitable substituent(s), andA is carbonyl, sulfonyl or lower alkylene, or a pharmaceutically acceptable salt thereof, which are useful as a testosterone 5.alpha.-reductase inhibitor.

Abstract: Indole derivatives of the formula ##STR1## and pharmaceutical compositions thereof. They are useful for treating or preventing testosterone 5-alpha-reductase-mediated diseases, such as alopecia, acnes and prostatism.

Abstract: An air-drying aqueous coating composition for electrodeposition comprising[A] a water-solubilized product or a water-dispersed product obtained by reacting (A-1) an epoxy resin and (A-2) a (semi)drying oil fatty acid-modified vinyl polymer having an acid value of 10 to 200 in such proportions that the solids weight ratio of the component (A-1) to the component (A-2) is from 90/10 to 5/95, and[B] an amphoteric organic solvent having affinity for component [A].

Abstract: The invention relates to a compound of antimicrobial activity of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkanoyl,R.sup.2 is hydrogen or ##STR2## in which R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen or lower alkanoyl,R.sup.3 is carboxy or a protected carboxy, and pharmaceutically acceptable salt thereof.

Abstract: The invention relates to compounds having aldose reductase-inhibitory activity of the formula: ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halogen, lower alkoxy or halo(lower)alkyl,R.sup.3 is phenyl(lower)alkyl which may have one or more substituent(s) selected from the group consisting of halogen, lower alkoxy, halo(lower)alkyl and lower alkyl,R.sup.4 is carboxy or protected carboxy,A is sulfur atom,Y is carbonyl, thiocarbonyl or sulfonyl andZ is lower alkylene,and pharmaceutically acceptable salts thereof, useful in treating diabetic complications.

Abstract: The invention relates to compounds of the formula: ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halogen, lower alkoxy or halo(lower)alkyl,R.sup.3 is dihalophenyl, naphthyl(lower)alkyl, phenyl(lower)alkyl substituted by one or two substituent(s) selected from the group consisting of halogen, lower alkoxy, halo(lower)alkyl and lower alkyl, or thienyl(lower)alkyl,R.sup.4 is carboxy or protected carboxy,Y is carbonyl, thiocarbonyl or sulfonyl andZ is lower alkylene, and pharmaceutically acceptable salts thereof, useful in the treatment of diabetic complications.